BPC-157 (Oral Stable Form) vs GHRP-2

Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.

✅ Stacking Partners — These compounds are commonly used together and may have synergistic effects.
BPC-157 (Oral Stable Form)GHRP-2
CategoryPeptidesPeptides
Standard DoseResearch indicates 250-500 mcg twice daily via oral capsule on empty stomach.Research indicates 100-300 mcg administered 1-3 times daily via subcutaneous injection.
TimingOn empty stomach, 30 minutes before meals. Twice daily dosing (morning and evening) provides consistent levels.On empty stomach, bedtime administration preferred. Wait 2+ hours after last meal.
Cycle Duration4-12 weeks. Oral form enables easier long-term use compared to injectable.8-16 week cycles.
Evidence Levelanimal_plus_anecdotalmoderate_human

Mechanism

Oral-stable BPC-157, typically formulated as the arginate salt, retains the same mechanism as standard BPC-157 — promoting angiogenesis via VEGFR2/PI3K/Akt/eNOS and Src-Caveolin-1-eNOS pathways, enhancing nitric oxide production, and stimulating tendon fibroblast growth and collagen formation. The arginate salt provides a protective buffer against gastric acid degradation, maintaining peptide integrity across a wider pH range. BPC-157 demonstrates remarkable native stability in human gastric juice (24+ hours), and the arginate form reportedly achieves 7-fold greater oral bioavailability compared to the acetate salt in preclinical studies.

Standard Dosing

Research indicates 250-500 mcg twice daily via oral capsule on empty stomach.

Timing

On empty stomach, 30 minutes before meals. Twice daily dosing (morning and evening) provides consistent levels.

Cycle Duration

4-12 weeks. Oral form enables easier long-term use compared to injectable.

Side Effects

  • Mild nausea
  • GI discomfort
  • Headache (rare)

Contraindications

  • Active cancer
  • Pregnancy and breastfeeding
  • Children under 18

Best Stacking Partners

TB-500GHK-Cu
B

GHRP-2

Peptides

Mechanism

GHRP-2 (Growth Hormone Releasing Peptide-2) is a synthetic hexapeptide GHS-R1a agonist that is the most potent of the GHRP family for GH release. It stimulates pituitary GH secretion through the ghrelin receptor while also modulating hypothalamic GHRH and somatostatin pathways. GHRP-2 increases GH, cortisol, prolactin, and ACTH release, but with less appetite stimulation than GHRP-6. It also has demonstrated anxiolytic properties and sleep-promoting effects.

Standard Dosing

Research indicates 100-300 mcg administered 1-3 times daily via subcutaneous injection.

Timing

On empty stomach, bedtime administration preferred. Wait 2+ hours after last meal.

Cycle Duration

8-16 week cycles.

Side Effects

  • Water retention
  • Moderate hunger increase (less than GHRP-6)
  • Cortisol elevation
  • Prolactin elevation
  • Tingling
  • Vivid dreams

Contraindications

  • Active cancer
  • Cushing's syndrome
  • Hyperprolactinemia
  • Pregnancy and breastfeeding

Best Stacking Partners

CJC-1295 (no DAC)SermorelinBPC-157

Not sure which is right for you?

Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.

Get Your Free Protocol →or take the assessment →